Products & Information Collection of New variant SARS-COV-2 (2019nCOV) -The New York variant B.1.526 lineage
Diagnostic antibodies and antigens for Companion Animal disease testing
● Rabbit
Diagnostic antibodies and antigens for Swine disease testing
Diagnostic antibodies and antigens for Avian disease testing
Diagnostic antibodies and antigens for Multiple animal disease testing
Diagnostic antibodies and antigens for Ruminant disease testing
● Deer
Diagnostic antibodies and antigens for infectious and non-infectious Equine/Horse disease testing
SOCAIL MEDIA
The world is in midst of the COVID-19 pandemic. Recently a new SARS-CoV-2 (2019nCOV)lineage (B.1.526) emerged in New York and spread rapidly. The New York variant B.1.526 lineage is characterised by six lineage-defining mutations in the spike protein, including D614G mutation and one at important residues in the receptor-binding domain (S477N or E484K)1.The combination of E484K or S477N with a D253G mutation of the B.1.526 lineage that might confer immune escape and the increased number of COVID-19 cases2. The position S477 is shown be S477N or S477G.
GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) New York variant B.1.526 lineage
Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) B.1.526 lineage, which will meet the evaluation of the efficacy of COVID19 vaccines and therapeutic antibodies.
SARS-COV-2 (2019nCOV) -New York variant B.1.526 lineage of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies
GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) -New York variant B.1.526 lineage
GeneMedi designed a mammalian expression codon-optimized spike mutation/deletion variant vector for COVID-19 SARS-COV-2 (2019nCOV) B.1.526 lineage.
Mutations of Spike protein in SARS-COV-2 (2019nCOV) B.1.526 lineage spread in New York
One spike mutation is at key residues in the RBD (S477N or E484K), two are in the N-terminal domain (T95I and D253G) and one is in loop 2 (A701V) 1. The position S477 is shown be S477N or S477G.
| Spike Mutation in SARS-COV-2 (2019nCOV) B.1.526 lineage | ||
| SP | L5F | |
| Spike-S1 Subunit N Terminal |
T95I | |
| D253G | Important residues mutation | |
| Spike-RBD | S477N/G or E484K | Important residues mutation |
| Spike-S1 Subunit | D614G | A popular mutation in different new SARS-CoV-2 lineage |
| Spike-S2 Subunit | A701V |
Reference
1.William A. Haseltine. New York Finds Its Own Covid Variants. The News Is Not Good. https://www.forbes.com/sites/williamhaseltine/2021/02/26/new-york-finds-its-own-covid-variants-the-news-is-not-good/?sh=4b0a20376de7.
2.Erica Lasek-Nesselquist, Pascal Lapierre, Erasmus Schneider, Kirsten St. George, View ORCID ProfileJanice Pata. The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State. doi: https://doi.org/10.1101/2021.02.26.21251868.
